Loading stock…

Kyowa Kirin Co., Ltd. (4151) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Kyowa Kirin Co., Ltd.

4151Market cap $7.31BPrice $14.0

Country🇯🇵Japan

SectorHealthcare

IndustryPharmaceuticals

Develops specialty pharmaceuticals for cancer, kidney disease, and rare disorders, built on cutting-edge antibody engineering. Its bone cancer drug Crysvita, born from Japanese biotech research, now treats patients worldwide after a landmark global licensing deal.

In Bastion Portfolios?

52W Return-4%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+1%3

Revenue Forecast

Rev CAGR (1y)-23%1

Rev CAGR (3y)+3%3

Rev CAGR (5y)+3%3

Earnings Forecast

EPS Growth Y+1-15%2

EPS Growth Y+2+62%10

EPS Growth Y+3-6%3

Quality

Margins

EBIT Margin21%7

Net Income Margin15%7

Free Cash Flow Margin19%8

Debt

Net Debt/EBITDA-1.910

Efficiency

ROE9%4

ROA7%7

Earnings Stability44

GEAR+AVERAGE48

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)165

P/E Ratio (Forward 3y)136

P/BV1.39

EV Multiples

EV/EBITDA Fwd87

EV/EBIT Fwd108

Yield

Free Cash Flow Yield8.9%9

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return-18%2

YTD return-11%3

Mid term

Price vs 52wHigh77%5

1 year return-4%4

Long term

3 year return-7%2

5 year return-34%2

Risk Shield

Price Risk

Beta0.76

Volatility37%5

Free Cash Flow

Free Cash Flow Margin19%8

Free Cash Flow Yield8.9%9

Quality

ROCE12%6

Earnings Stability44

Net Debt/EBITDA-1.910

02Growth

Is it actually growing, and how fast?

4151Kyowa Kirin Co.

Revenue FY25$3.2B

GROWTH RATING↗

WEAK16 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-23%1

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-15%2

EPS growth, FY27E+62%10

EPS growth, FY28E-6%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 1%/yr over the last 3 years and is set to keep growing around 3%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 84% of companies worldwide.

Revenue grew 1%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

Earnings are set to fall even as revenue grows (EPS about -6%/yr vs revenue 3%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-18%2

YTD return-11%3

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return-4%4

3-year return-7%2

5-year return-34%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 4% over the past year, now 23% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.4% over three years and -34% over five), behind 80% of the market.

The stock is underperforming over three months (-18%) and so far this year (-11%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Kyowa Kirin Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

4151Kyowa Kirin Co.

Revenue FY25$3.2B

GROWTH RATING↗

WEAK16 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y-23%1

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-15%2

EPS growth, FY27E+62%10

EPS growth, FY28E-6%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 1%/yr over the last 3 years and is set to keep growing around 3%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 84% of companies worldwide.

Revenue grew 1%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

Earnings are set to fall even as revenue grows (EPS about -6%/yr vs revenue 3%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-18%2

YTD return-11%3

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return-4%4

3-year return-7%2

5-year return-34%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 4% over the past year, now 23% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.4% over three years and -34% over five), behind 80% of the market.

The stock is underperforming over three months (-18%) and so far this year (-11%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Kyowa Kirin Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community